BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nycomed and Ceremed Announce Licensing and Distribution Agreement


10/24/2007 6:26:11 AM

LOS ANGELES, Oct. 24 /PRNewswire/ -- Ostene® is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or increase the risk of surgical infections, including MRSA. This novel biomaterial is used in cardiac, orthopedic, and neurosurgery and has additional applications as a safe, soluble delivery vehicle for a variety of therapeutic agents, from antibiotics to bone growth factors. Ostene® is FDA-approved and carries a CE mark.

Ostene® is a sterile mixture of water-soluble alkylene oxide copolymers developed as an affordable, easy-to-handle synthetic bone hemostasis material that does not increase the risk to patients. Wax-like and malleable during application, the biomaterial dissolves rapidly and is eliminated from the body unchanged shortly after surgery. Ceremed is currently developing next generation of Ostene®with antibiotics specifically designed to prevent hospital-acquired surgical infection.

The use of Ostene® in cardiac surgery may help reduce the risk of sternal wound infection and prevent the post-operative separation of the sternum, much feared complications. The benefits of Ostene® may be particularly significant for a growing high-risk group of diabetics and overweight patients who currently represent approximately 25% of more than 640,000 open heart surgery procedures performed each year in the US alone.

Ceremed president and CEO Dr. Tadeusz Wellisz said, "The agreement with Nycomed provides us with a partner who will help us pursue a full cardiac, orthopedic, and neurosurgical development program for Ostene® in Europe. We appreciate Nycomed's expertise in this territory, and we look forward to working with Nycomed's tissue management team on bringing Ostene® to patients throughout Europe. Ostene®'s unique anti-bacterial properties are particularly significant now that we are battling the threat of hospital-acquired infections, especially MRSA."

About The Companies:

Ceremed, Inc. is a privately held California medical device corporation formed in 2002 by a surgeon and a group of scientists from the University of Southern California. The company has unique expertise and a portfolio of innovative proprietary technology in the field of soluble alkylene oxide copolymers. These polymers have multiple medical applications, including bone hemostasis and a delivery system for a variety of therapeutic agents. Ceremed is currently developing new products and new applications for its core technology.

Nycomed is a pharmaceutical company active in tissue management as well as cardiology, gastroenterology, osteoporosis, respiratory, and pain management. It provides prescription drugs, medical devices, and, in selected markets, OTC drugs to hospitals and individual doctors. New products are sourced both from own research and from external partners and made available in 50 countries throughout Europe and in fast-growing markets such as Latin America, Russia, and the Asia-Pacific. Nycomed is privately held with the combined group annual sales of euro 3.4 billion (2006 results).

For more information, please visit http://www.ceremed.com

Source: Ceremed, Inc.



Read at BioSpace.com

Nycomed
Ceremed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES